In a study presented last week, researchers measured the effect of gargling and nasal rinsing with a saline solution on symptoms and hospitalization rates in patients with Covid.
They found hospitalization rates for people who gargled or nasal rinsed salt water were up to 40 percent lower than those who did not.
Between 2020 and 2022, the team evaluated 9,398 adults between 18 and 65 years old who had tested positive for Covid via a PCR test. Of those, 58 were selected to follow either a low-dose or high-dose saline regimen mixed with eight ounces of warm water.
The low-dose regimen was 2.13 grams of saline - about one-third a teaspoon - and the high-dose was six grams - about one and one-quarter a teaspoon. Participants gargled and did nasal rinsing four times a day for 14 days.
The control group that hadn't been instructed to gargle salt water or nasal rinse had a 58.8 percent hospitalization rate. The hospitalization rate for participants on the low-dose regimen dropped to 18.5 percent, and the rate for the high-dose group was 21.4 percent. This was up to 40 percent lower than the control group.
Dr Zach Rubin, an allergist and spokesperson for the American College of Allergy, Asthma & Immunology (ACAAI), told Medscape: 'This is a type of intervention that is low risk with some small [SIC!] potential benefit.'
When cell lysates transfected with S protein were incubated with nattokinase, the S protein was degraded in a dose- and time-dependent manner. Immunofluorescence analysis showed that S protein on the cell surface was degraded when nattokinase was added to the culture medium. Thus, our findings suggest that nattokinase exhibits potential for the inhibition of SARS-CoV-2 infection via S protein degradation.
In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C.
Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms.
To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d. The goal should be to raise 25(OH)D concentrations above 40-60 ng/mL (100-150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.
Large, well-designed randomised control study shows Ivermectin efficacy in preventing and treating COVID-19. Of the 200 participants who received ivermectin, 30 showed laboratory-confirmed infections between Days 1 and 28 of the study. Of the 199 participants who received the placebo, 105 showed infections in the same period. For those who like Fisher’s p-value, this renders a p < 0,0001. There were no unexpected side effects, and safety and tolerability were once again demonstrated. Mortality data is not available, but this study occurred during the omicron infection period, where mortality was markedly reduced compared to the prior strains.
“Conclusions: The datasets provide strong evidence that low D3 is a predictor rather than just a side effect of the infection. Despite ongoing vaccinations, we recommend raising serum 25(OH)D levels to above 50 ng/mL to prevent or mitigate new outbreaks due to escape mutations or decreasing antibody activity.“
In the present study, we characterized in detail the nuclear transport inhibitory properties of ivermectin, demonstrating that it is a broad-spectrum inhibitor of importin α/β nuclear import, with no effect on a range of other nuclear import pathways, including that mediated by importin β1 alone. Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively. Ivermectin would appear to be an invaluable tool for the study of protein nuclear import, as well as the basis for future development of antiviral agents.
FLCCC Alliance - Front Line COVID-19 Critical Care Alliance: Prevention & Treatment Protocols for COVID-19
Think you meant covid-19 in title!